Weight loss candidate drug nimacimab safety approved. Skye (SKYE.US) stock price soared 11%.
Skye Bioscience's stock price soared 11%, benefiting from the safety differences between its weight loss candidate drug nimacimab and novo-nordisk a/s's monlunabant.
Sector Update: Health Care Stocks Retreat Late Afternoon
Morgan Stanley Starts Structure Therapeutics at Overweight
Skye Stock Rallies 22% Following Weight-loss Drug Update
Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65
Cantor Fitzgerald analyst Prakhar Agrawal maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success
Structure Therapeutics Price Target Announced at $118.00/Share by Morgan Stanley